ARDX Ardelyx Inc.

3.93
-0.05  -1%
Previous Close 3.98
Open 3.97
Price To Book 1.49
Market Cap 243871241
Shares 62,053,751
Volume 184,245
Short Ratio 2.08
Av. Daily Volume 330,753

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing announced September 13, 2018.
Tenapanor (T3MPO-2)
Constipation-predominant irritable bowel syndrome (IBS-C)
Onset of action trial data released November 21, 2017 - noted significantly reduced serum potassium in patients. Development to be discontinued.
RDX7675
Hyperkalemia
Phase 3 released February 15, 2017 - primary endpoint met. Data from second Phase 3 trial due 2019.
Tenapanor
Hyperphosphatemia in end-stage renal disease (ESRD) patients
Phase 3 data released May 12, 2017. Primary endpoint met - however, competitive concerns raised.
Tenapanor (T3MPO-1)
Constipation-predominant irritable bowel syndrome (IBS-C)

Latest News

  1. Analysis: Positioning to Benefit within Ardelyx, AXT, TG Therapeutics, MarineMax, Oclaro, and BioCryst Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
  2. Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting
  3. Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders
  4. How Does Investing In Ardelyx Inc (NASDAQ:ARDX) Impact Your Portfolio?
  5. Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration
  6. Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption
  7. Edited Transcript of ARDX earnings conference call or presentation 7-Aug-18 8:30pm GMT
  8. Consolidated Research: 2018 Summary Expectations for PDF Solutions, MYOS RENS Technology, Aldeyra Therapeutics, The Ensign Group, Everi, and Ardelyx — Fundamental Analysis, Key Performance Indications
  9. Ardelyx: 2Q Earnings Snapshot
  10. Ardelyx Reports Second Quarter 2018 Financial Results and Recent Highlights
  11. Ardelyx, Inc. to Host Earnings Call
  12. Ardelyx Announces Date of Second Quarter 2018 Financial Results and Conference Call
  13. Free Technical Reports on Array BioPharma and Three Additional Biotech Equities
  14. Ardelyx to Present at the Jefferies 2018 Global Healthcare Conference
  15. Why Ardelyx Inc. Is Down by Double Digits for a Second Day in a Row
  16. Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing
  17. Ardelyx Announces Pricing of Public Offering of Common Stock
  18. Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict
  19. Ardelyx Raises $50 Million in Loan Agreement with Solar Capital and Bridge Bank